Emcitate

No identified source reports a budget impact model for tiratricol. One published model estimates a cost-based-plus annual price in the EU context. Its maximum-cost scenario yields €27,600 per person per year, and scenarios with lower costs or more treated individuals yield €5,300 to €16,500. The authors report that the number of patients and the cost of capital are the parameters with the largest influence on price, and they cite a company projection of €63,500 to €95,000 per person per year.

In Germany, the G-BA resolution estimates approximately 40 to 110 patients in the statutory health insurance target population and annual treatment costs of €44,216.13 to €972,754.87 per patient after statutory rebates. The lower limit uses the 175 μg/day starting dose, and the upper limit uses the maximum weight-based dose at an average body weight of 77.7 kg. The G-BA identifies a hint of a non-quantifiable additional benefit, with a high risk of bias from the single-arm, open-label design of Triac Trial I. IQWiG's assessment is limited to patient numbers and costs in the manufacturer's dossier. The French Transparency Committee rated the clinical benefit insufficient to justify public funding because efficacy was demonstrated for biological endpoints only, in a non-comparative study.